Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

Core Insights - Humacyte has submitted a Marketing Authorization Application (MAA) for its acellular tissue engineered vessel, Symvess, to the Israel Ministry of Health for arterial trauma repair, with plans for hospital-by-hospital availability prior to approval [1][2] - The company is preparing for global expansion of Symvess, leveraging FDA approval and clinical results to expedite commercialization in multiple countries, including the Middle East [2] Company Overview - Humacyte, Inc. is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at commercial scale [1][12] - The company aims to transform medical practices by delivering advanced tissue constructs and organ systems to improve patient outcomes [12] Product Details - Symvess is designed for urgent revascularization in adults with extremity arterial injuries when autologous vein grafts are not feasible, providing an off-the-shelf solution that saves critical surgical time [2][4] - Clinical trials have shown Symvess to have low infection rates and high limb salvage rates, with a notable humanitarian program in Ukraine demonstrating 100% survival and zero amputations among treated patients [2] Regulatory Status - The FDA approved Humacyte's Biologics License Application for Symvess in December 2024, and the product is currently in late-stage clinical trials for other vascular applications [12] - Symvess is still considered investigational for uses beyond FDA approval in extremity vascular trauma [3] Safety Information - Important safety information includes risks of graft failure, thrombosis, and potential transmission of infectious diseases, with common adverse reactions being vascular graft thrombosis, fever, and pain [5][9][11]